This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pitot, H. C. Articles by Erlichman, C. Search for Related Content PubMed PubMed Citation Articles by Pitot, H. C. Articles by Erlichman, C.

A Phase I Study of Bizelesin (NSC 615291) in Patients with Advanced Solid Tumors¹

Divisions of Medical Oncology [H. C. P., A. A. A., J. R., R. M. G., C. E.] and Oncology Research [J. M. R., M. M. A., P. G. B., D. R.] and Section of Biostatistics [J. A. S., P. A.], Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905

Purpose: To evaluate the toxicities, characterize the pharmacokinetics, and determine the maximum-tolerated dose of bizelesin administered once every 4 weeks.

Patients and Methods: Patients with advanced solid tumors received escalating doses of bizelesin as an i.v. push every 4 weeks. Pharmacokinetic studies were performed with the first treatment cycle.

Results: Nineteen eligible patients received a total of 54 courses of bizelesin at doses ranging from 0.1 to 1 µg/m². Dose-limiting toxicity of neutropenia was seen in 2 of 4 patients treated at the 1 µg/m² dose level. Nonhematological toxicity was generally mild with maximum toxicity being grade 2 per National Cancer Institute Common Toxicity Criteria. No objective responses were seen in the 19 eligible patients. An L1210 bioassay was used to determine bizelesin plasma levels. The terminal elimination half-life was 140 min at the recommended Phase II dose. The area under the concentration time curve increased in proportion to administered dose, and the clearance remained constant over the dose range studied. Correlation analysis demonstrated relationships between dose and area under the concentration with cycle 1 hematological parameters, including absolute neutrophil and leukocyte nadirs.

Conclusion: Bizelesin administered every 4 weeks as an i.v. push is well tolerated with dose-limiting toxicity of neutropenia. The maximum-tolerated dose (and recommended Phase II dose) is 0.8 µg/m² administered once every 4 weeks.

This article has been cited by other articles:

				K. Kiakos, A. Sato, T. Asao, P. J. McHugh, M. Lee, and J. A. Hartley DNA sequence selective adenine alkylation, mechanism of adduct repair, and in vivo antitumor activity of the novel achiral seco-amino-cyclopropylbenz[e]indolone analogue of duocarmycin AS-I-145 Mol. Cancer Ther., October 1, 2007; 6(10): 2708 - 2718. [Abstract] [Full Text] [PDF]

				J. A. Hartley, V. J. Spanswick, N. Brooks, P. H. Clingen, P. J. McHugh, D. Hochhauser, R. B. Pedley, L. R. Kelland, M. C. Alley, R. Schultz, et al. SJG-136 (NSC 694501), a Novel Rationally Designed DNA Minor Groove Interstrand Cross-Linking Agent with Potent and Broad Spectrum Antitumor Activity: Part 1: Cellular Pharmacology, In vitro and Initial In vivo Antitumor Activity Cancer Res., September 15, 2004; 64(18): 6693 - 6699. [Abstract] [Full Text] [PDF]

				Q. Zhou and S. E. Rokita A general strategy for target-promoted alkylation in biological systems PNAS, December 23, 2003; 100(26): 15452 - 15457. [Abstract] [Full Text] [PDF]

				G. H. Schwartz, A. Patnaik, L. A. Hammond, J. Rizzo, K. Berg, D. D. Von Hoff, and E. K. Rowinsky A phase I study of bizelesin, a highly potent and selective DNA-interactive agent, in patients with advanced solid malignancies Ann. Onc., May 1, 2003; 14(5): 775 - 782. [Abstract] [Full Text] [PDF]